Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation

Activating KRAS mutations in lung adenocarcinoma are characterized with treatment resistance and poor prognosis. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase, apatinib has been proven successful in advanced gastric cancer and breast cancer....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Onco Targets Ther
Asıl Yazarlar: Zeng, Da-xiong, Wang, Chang-guo, Huang, Jian-an, Jiang, Jun-hong
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2017
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5584919/
https://ncbi.nlm.nih.gov/pubmed/28894382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S139520
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller